Glenn Goddard has nearly two decades of experience leading business and financial operations for public and private companies in the biotechnology industry. Prior to joining Intellia, Glenn served as the Chief Financial Officer at Generation Bio Company, where he led all financial functions, investor relations, information technologies and certain operational functions. During his time at Generation Bio, he closed a $100 million private financing and a long-term lease deal for 75,000 square feet of lab and office space. Before joining Generation Bio, Glenn served as Senior Vice President of Finance and Principal Financial Officer of Agios Pharmaceuticals, where he led the company’s strategic financings efforts raising more than $700 million in equity financings, including a private crossover financing, an initial public offering and several subsequent follow-on offerings. In addition, Glenn was responsible for all financial functions of the company, including strategic planning and analysis, investor relations, treasury, tax, finance and accounting. He also was responsible for information technologies, certain operational functions and supporting strategic partnering efforts.
Previously, Glenn held various senior-level financial management positions at both Archemix, a privately held oligonucleotide platform-based biopharmaceutical company, and Immunogen, a publicly traded oncology-focused biopharmaceutical company. Earlier in his career, Glenn was an audit supervisor at Ernst & Young LLP and a business advisory manager at Feeley & Driscoll, P.C. Glenn is a graduate of Bentley College, where he earned a B.S. in Accountancy and is a Certified Public Accountant in the Commonwealth of Massachusetts.
What is Glenn Goddard's net worth?
The estimated net worth of Glenn Goddard is at least $501.27 thousand as of January 3rd, 2024. Mr. Goddard owns 40,585 shares of Intellia Therapeutics stock worth more than $501,265 as of March 27th. This net worth estimate does not reflect any other investments that Mr. Goddard may own. Learn More about Glenn Goddard's net worth.
How do I contact Glenn Goddard?
Has Glenn Goddard been buying or selling shares of Intellia Therapeutics?
Glenn Goddard has not been actively trading shares of Intellia Therapeutics during the last quarter. Most recently, Glenn Goddard sold 5,365 shares of the business's stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $29.46, for a transaction totalling $158,052.90. Following the completion of the sale, the chief financial officer now directly owns 40,585 shares of the company's stock, valued at $1,195,634.10. Learn More on Glenn Goddard's trading history.
Who are Intellia Therapeutics' active insiders?
Intellia Therapeutics' insider roster includes James Basta (EVP, General Counsel and Corporate Secretary), William Chase (Director), Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Michael Dube (CAO), Jean-Francois Formela (Director), Glenn Goddard (CFO), Jesse Goodman (Director), J III (EVP), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), Birgit Schultes (EVP), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, Intellia Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,003,000.00. In the last year, insiders at the sold shares 10 times. They sold a total of 67,752 shares worth more than $677,745.91. The most recent insider tranaction occured on January, 5th when CEO John M Leonard sold 34,146 shares worth more than $314,484.66. Insiders at Intellia Therapeutics own 3.1% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 1/5/2026.
